Business and Finance

Rockville-based Emergent BioSolutions Inc., which supplies the government with the only regulator-approved vaccine for Anthrax, boosted its full-year forecast for sales and earnings based on rising sales of that vaccine.

The company now forecasts full-year revenue of between $275 million and $300 million, up from a forecast in May of between $235 million and $255 million. It expects 2010 net income of between $40 million and $50 million, compared to its previous forecast of between $20 million and $30 million.

As much as $190 million in 2010 revenue will come in the second half of the year, it says, after a contract modification that increases the number of doses of BioThrax the government will buy for its stockpile this year.

“We are extremely pleased with the results of our continuous process improvement program for BioThrax and expect this program to drive the maintenance of positive production metrics going forward,” said Emergent BioSolutions (NYSE: EBS) Chief Operating Officer Daniel Abdun-Nabi.

Source